Michael Nip Hall

Michael Nip Hall is a distinguished American-Swiss molecular biologist and Professor at the Biozentrum of the University of Basel, Switzerland. He has held this position since 1992, following his appointment as Assistant Professor in 1987. Hall previously held positions at the University of California, San Francisco and conducted postdoctoral research at the Pasteur Institute in Paris.

Dr. Hall earned his B.S. in Zoology from the University of North Carolina at Chapel Hill in 1976 and his Ph.D. from Harvard University in 1981. His doctoral research focused on "Genetic studies on the regulation of the major outer membrane porin proteins of Escherichia coli K-12" under advisor Thomas J. Silhavy.

Professor Hall is a pioneer in the field of cell growth regulation and is best known for discovering the TOR (Target of Rapamycin) protein, which is central to understanding cell growth control. His research focuses on the molecular mechanisms that control growth and metabolism in health and disease, with particular emphasis on the TOR signaling pathway. Hall studies TOR signaling using multiple model systems, including yeast (Saccharomyces cerevisiae), mammalian cells, mice, and human tumors, employing biochemical, genetic, and cell biological approaches.

His publication record demonstrates a strong focus on mTOR signaling, cancer metabolism, and cellular growth regulation. Recent work has explored connections between mTOR signaling and various disease states including cancer, metabolic disorders, and aging. His research has increasingly incorporated multi-omics approaches to understand complex disease mechanisms.

• Balzan Prize for Biological Mechanisms of Ageing (2024)
• Grande Médaille, French Academy of Sciences (2023)
• Sjöberg Prize (2020)
• Albert Lasker Award for Basic Medical Research (2017)
• Canada Gairdner International Award (2015)
• Breakthrough Prize in Life Sciences (2014)

As Vice Director of the Biozentrum (2002-2009, 2013-2016) and Chairman of the European Molecular Biology Organization Council (2021-2022), Hall has played significant leadership roles in academic research. He currently serves on the Board of Trustees of the Louis-Jeantet Foundation and has received continuous research funding including an ERC Synergy Grant (2014-2020). His laboratory continues to investigate fundamental mechanisms of cell growth with implications for understanding and treating numerous human diseases.

Professor Hall leads an active research group at the Biozentrum focusing on TOR signaling and its role in cell growth control. His laboratory employs a multidisciplinary approach, combining biochemical, genetic, and cell biological techniques to unravel the complex mechanisms of TOR signaling in various model systems.